# Insulet Corporation (PODD)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $10.83B  
**Price:** $150.71 (-5.58%)

> Insulet Corporation is a medical device company specializing in insulin delivery technologies for people living with insulin‑dependent diabetes. The company focuses on its Omnipod platform, a family of tubeless, wearable, pod-based insulin management systems designed to provide continuous subcutaneous insulin infusion without the need for multiple daily injections. Key offerings include the Omnipod 5 automated insulin delivery system, which incorporates a proprietary algorithm and connects with compatible continuous glucose monitors via Bluetooth, and the Omnipod DASH system, which is controlled through a handheld, smartphone-like device. Insulet also supplies wearable drug-delivery pods for use in certain oncology-related treatments, such as the Neulasta Onpro kit. Products are distributed through the pharmacy channel and independent distributors, serving patients in the United States and international markets. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet today plays a notable role in the healthcare and medical devices sector by providing device-based solutions that support day-to-day diabetes management.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.71B | $1.94B | $474M | $247M | — |
| 2024 | $2.07B | $1.45B | $309M | $418M | — |
| 2023 | $1.70B | $1.16B | $220M | $206M | — |
| 2022 | $1.06B | $806M | $38M | $5M | — |
| 2021 | $1.04B | $752M | $126M | $17M | — |
| 2020 | $904M | $582M | $52M | $7M | — |
| 2019 | $738M | $480M | $50M | $12M | — |
| 2018 | $564M | $370M | $27M | $3M | — |
| 2017 | $464M | $277M | -$7M | -$27M | — |
| 2016 | $367M | $211M | -$11M | -$29M | — |
| 2015 | $264M | $133M | -$49M | -$74M | — |
| 2014 | $231M | $127M | -$9M | -$52M | — |
| 2013 | $247M | $112M | -$29M | -$45M | — |
| 2012 | $211M | $92M | -$36M | -$52M | — |
| 2011 | $152M | $67M | -$42M | -$46M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3.19B | $1.68B | $1.52B | — | — |
| 2024 | $3.09B | $1.88B | $1.21B | — | — |
| 2023 | $2.59B | $1.86B | $733M | — | — |
| 2022 | $2.25B | $1.77B | $476M | — | $1.40B |
| 2021 | $2.05B | $1.49B | $556M | — | $1.27B |
| 2020 | $1.87B | $1.27B | $604M | $907M | $1.06B |
| 2019 | $1.14B | $1.07B | $76M | $214M | $888M |
| 2018 | $929M | $717M | $212M | $114M | $592M |
| 2017 | $817M | $658M | $159M | $273M | $566M |
| 2016 | $457M | $393M | $63M | $137M | $333M |
| 2015 | $275M | $241M | $34M | $123M | $172M |
| 2014 | $297M | $213M | $84M | $151M | $164M |
| 2013 | $288M | $163M | $125M | $150M | $114M |
| 2012 | $198M | $154M | $44M | $57M | $118M |
| 2011 | $221M | $139M | $83M | $94M | $109M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $569M | $192M | $378M |
| 2024 | $430M | $125M | $305M |
| 2023 | $146M | $76M | $70M |
| 2022 | $119M | $123M | -$4M |
| 2021 | -$68M | $112M | -$180M |
| 2020 | $84M | $129M | -$45M |
| 2019 | $98M | $164M | -$65M |
| 2018 | $36M | $157M | -$122M |
| 2017 | $41M | $74M | -$33M |
| 2016 | $16M | $22M | -$6M |
| 2015 | -$13M | $11M | -$23M |
| 2014 | $9M | $11M | -$3M |
| 2013 | $3M | $7M | -$4M |
| 2012 | -$29M | $11M | -$40M |
| 2011 | -$25M | $11M | -$37M |

Source: [CompaniesByCap](https://companiesbycap.com/company/PODD)